DRUG · Mapped RxNorm record
Tarlatamab
Normalized identity: tarlatamabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
NCT07637513
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Durvalumab
Normalized identity: durvalumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedTarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Limited Stage Small-Cell Lung Cancerunresolved
Interventions
TarlatamabDRUG · verified · RxNorm: tarlatamab
DurvalumabDRUG · verified · RxNorm: durvalumab
Sponsors & collaborators
PrECOG, LLC.lead sponsor
Amgencollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07637513 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.